Compare Organon & Co. Common Stock (OGN) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Organon & Co. Common Stock trades at $13.77 (market cap $3.61B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $25.33 (market cap $158.98M). The key difference: Organon & Co. Common Stock is far larger — about 22.7× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Roundhill Russell 2000 0DTE Covered Call Strat ETF for 56 Days on average.
| OGN | RDTE | |
|---|---|---|
Market Cap | $3.61B | $158.98M |
Volume | 1,808,049 | 121,355 |
Sector | Health | Income / Options Overlay |
52-Week High | $13.81 | $33.66 |
52-Week Low | $5.70 | $25.43 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
RDTE (Roundhill Russell 2000 0DTE Covered Call Strategy ETF) trades at $25.91, down 0.54% with bearish technical indicators showing 17 sell signals versus 0 buy signals. The ETF faces capital erosion concerns despite offering high dividend yields through its covered call strategy on Russell 2000 small-cap stocks. Recent dividend payments have ranged from $0.10 to $0.23 per share, but the fund's income generation comes with significant price depreciation risk.
The outlook remains challenging as technical analysis indicates strong bearish momentum with moving averages unanimously signaling sell. Fundamental data is limited but the covered call strategy exposes investors to capped upside potential during market rallies while providing limited downside protection. Key risks include small-cap volatility and the structural limitations of 0DTE options strategies in generating sustainable income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
